Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) ; volume:25 ; number:10 ; day:8 ; month:9 ; year:2023 ; pages:1181-1189 ; date:10.2023
Current oncology reports ; 25, Heft 10 (8.9.2023), 1181-1189, 10.2023
- Creator
-
Simon, Florian
Bohn, Jan-Paul
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-023-01454-w
- URN
-
urn:nbn:de:101:1-2023122722581642292586
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simon, Florian
- Bohn, Jan-Paul
- SpringerLink (Online service)
Other Objects (12)
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Whole exome sequencing of chronic lymphocytic leukemia (CLL) : extending the number of recurrently mutated genes in CLL and detailed analysis of the putative CLL driver mutations in XPO1
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Whole exome sequencing of chronic lymphocytic leukemia (CLL) : extending the number of recurrently mutated genes in CLL and detailed analysis of the putative CLL driver mutations in XPO1
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
Update on the management of relapsed/refractory chronic lymphocytic leukemia
Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Whole exome sequencing of chronic lymphocytic leukemia (CLL) : extending the number of recurrently mutated genes in CLL and detailed analysis of the putative CLL driver mutations in XPO1
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study